Oncology Drug Reference Sheet: Motixafortide

The first innovation in stem cell mobilization for multiple myeloma in a decade, motixafortide (Aphexda^™) received U.S. Food and Drug Administration approval on September 11, 2023. The drug’s clinical trial demonstrated that one dose of motixafortide plus filgrastim enabled a majority of patients to achieve the collection goal of at least six million hematopoietic stem cells.